Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma

BACKGROUND: To characterize genomic determinants of response to pembrolizumab in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) in the KEYNOTE-012 study. METHODS: Associations between biomarkers (tumor mutational burden (TMB), neoantigen load (NL), 18-gene T-cell-inflamed g...

Descripción completa

Detalles Bibliográficos
Autores principales: Haddad, Robert I, Seiwert, Tanguy Y, Chow, Laura Q M, Gupta, Shilpa, Weiss, Jared, Gluck, Iris, Eder, Joseph P, Burtness, Barbara, Tahara, Makoto, Keam, Bhumsuk, Kang, Hyunseok, Muro, Kei, Albright, Andrew, Mogg, Robin, Ayers, Mark, Huang, Lingkang, Lunceford, Jared, Cristescu, Razvan, Cheng, Jonathan, Mehra, Ranee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883256/
https://www.ncbi.nlm.nih.gov/pubmed/35217573
http://dx.doi.org/10.1136/jitc-2021-003026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883256/
https://www.ncbi.nlm.nih.gov/pubmed/35217573
http://dx.doi.org/10.1136/jitc-2021-003026

Ejemplares similares